Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Manufacturing

OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

Read more
OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States

Trending Articles

  1. Abzena advances immunogenicity risk assessment in biologic drug development New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
  2. Piramal Pharma Solutions awards Riverview and Digwal for patient centricity Two sites recognised for innovative initiatives that put patients first
  3. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  4. Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
  5. MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled

You may also like

Manufacturing

OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States
Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Manufacturing

How to execute a successful remediation strategy

NSF’s experts share guidance on building sustainable compliance and avoiding quick fixes
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Regulatory

Compliance ≠ Quality: why “meeting the standard” isn’t enough

In pharma manufacturing, regulatory compliance is non-negotiable. Whether it’s 21 CFR Part 11, EU Annex 11, or PIC/S PE-009, every manufacturer understands the need for validated systems, traceable records, and secure data
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Packaging

Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe

The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Subscribe now